Maximizing Protein Expression in Filamentous Fungi - Filamentous fungi are efficient protein producers that hold great promise for shortening product development cycles. - BioPharm International

ADVERTISEMENT

Maximizing Protein Expression in Filamentous Fungi
Filamentous fungi are efficient protein producers that hold great promise for shortening product development cycles.


BioPharm International
Volume 19, Issue 5




Various approaches to improve transcription have been used in fungi. For the expression of heterologous genes, especially of nonfungal origin, codon-optimized, synthetic genes can improve the transcription rate. The gene is adapted to the preferred codon usage of the host strain, based on the codon usage data of a large number of well-expressed or secreted proteins. To obtain high- level expression of a particular gene, a well-established procedure is targeting multiple copies of the recombinant gene constructs to the locus of a highly expressed endogenous gene. An advantage of such a gene replacement is knowing that the integration occurs in a region of the genome that is actively transcribed. When the target locus is that of a highly-expressed secreted protein, the reduced load on the secretion pathway may facilitate expression and secretion of the recombinant gene product.

For the secretion of foreign proteins, fusion strategies are used to facilitate translocation in the secretion pathway and to protect the heterologous protein from degrading. An amino terminal fusion with an efficiently secreted protein is generally preferred. A truncated form of the A. niger glucoamylase (GII) gene has been used successfully in several fungal hosts.3 To separate the fusion partner from the target gene, one can use the endogenous secretion machinery of the fungal host or engineer cleavage sites between the fusion partner and target. During normal fungal protein secretion, passage of the protein through the cell membrane is accompanied by proteolytic cleavage of the signal sequence from the mature protein in a sequence-specific manner. When such a recognition sequence is engineered between the fusion partner and target protein, cleavage results, with the secretion of the protein of interest separated from the fusion partner. Sometimes, however, it is desirable to maintain intact fusion proteins, if they are more stable than the corresponding independent target protein. In those cases, protease recognition sites that are not recognized by the cellular secretion machinery can be engineered between the secretion partner and target protein, with subsequent in vitro cleavage and separation of the target from the fusion partner.

Reducing proteolytic degradation. One of the major challenges in fungal biotechnology, especially for the production of pharmaceutical proteins, is that the recombinant protein is often degraded by proteases of the fungal host. Reducing protease activities can be achieved by combining different approaches. One involves selecting or screening for fungal host strains with low protease activity. This can be accomplished either by direct selection, using "suicide" selection substrates, or by mutagenesis and screening for reduced protease activity on indicator plates. Other approaches are identifying and inactivating genes for specific proteases, identifying and modifying wide-domain protease regulators, and optimizing medium composition and fermentation protocols.4 The isolation of mutant strains that can produce higher levels of a specific heterologous protein with subsequent removal of the expression construct is another strategy used to produce host strains with reduced proteolytic activity.5


Figure 1. At left is a microscopic image of wild type Chrysosporium lucknowense. The filamentous nature of this organism results in highly viscous cultures, surface matting, and clumping. A nonviscous mutant "propagule" is shown at right. The nonfilamentous strain offers advantages for high-throughput screening, gene expression, and protein production.
Post-translational modification. Protein glycosylation is an important consideration in the production of eukaryotic proteins and is especially important for therapeutics. Non-native glycosylation can influence serum half-life, function, and immunogenicity of therapeutic proteins. Considerable progress has been made in modifying the glycosylation patterns of fungi, especially in the methylotrophic yeast Pichia pastoris. 6 While there has been considerable effort in understanding glycan biosynthesis,3 the progress toward glycan modification in filamentous fungi is not as advanced as in Pichia. Modification of native fungal glycan structures to make them human-identical or human-compatible, whether by in vivo methods or by in vitro remodeling7 will be important if filamentous fungi are going to be viable alternative systems for the production of proteins of pharmaceutical interest.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pandemic Vaccine Facility Dedicated in Texas
September 19, 2014
GSK Fined in China Bribery Scandal
September 19, 2014
Guideline Delineates How to Implement GS1 Standards to Support DSCSA
September 19, 2014
GPhA Supports Restricted Access Bill
September 18, 2014
Baxter Initiates Voluntary Recall of Potassium Chloride Injection
September 17, 2014
Author Guidelines
Source: BioPharm International,
Click here